Recently a founder tells me the submission is still months out, And I ask what the team will be doing
The global regulatory landscape for Software as a Medical Device (SaMD) has reached a definitive inflection point as of March
A company that treats regulation as paperwork feels that movement as risk. A company that has built real regulatory firepower
I Spent the Last Week Reading Everything I Could Find on Abbott’s Libre Duo. Here Is What Genuinely Impressed Me
By moving from reactive observation to proactive, sensor-driven therapy, 2026 is the year we finally give Parkinson’s patients their independence
The gold standard of molecular diagnostics is undergoing a fundamental phase shift that renders the traditional laboratory model obsolete. As
